Complications of myeloma and its treatments

Serous macular detachment, yellow macular deposits, and prominent middle limiting membrane in multiple myeloma. Dogan B et al. Ther Clin Risk Manag. 2015 Apr 30;11:683-9. doi: 10.2147/TCRM.S79232. eCollection 2015. Contribution of Clostridium difficile infection to the development of lower gastrointestinal adverse events during autologous stem cell transplantation. Apewokin S et al, Transpl Infect Dis. 2015 May 19. doi: 10.1111/tid.12403. [Epub ahead of…

Current treatments

Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma. Poenisch W et al. J Cancer Res Clin Oncol. 2015 May 15. [Epub ahead of print]. High-dose therapy and autologous stem cell transplant in older adults with multiple myeloma. Wildes TM et al. Bone Marrow Transplant. 2015 May 11. doi: 10.1038/bmt.2015.106. [Epub…

Diagnostic tests and prognostic indicators

Plasma cell morphology in multiple myeloma and related disorders. Ribourtout B et al. Morphologie. 2015 Apr 18. pii: S1286-0115(15)00021-1. doi: 10.1016/j.morpho.2015.02.001. [Epub ahead of print]. Proteomic Analysis for Finding Serum Pathogenic Factors and Potential Biomarkers in Multiple Myeloma. Zhang HT et al. Chin Med J (Engl). 2015 20th Apr;128(8):1108-1113. doi: 10.4103/0366-6999.155112. Measurement of Proteasome Activity in Peripheral Blood Mononuclear Cells as an Indicator of…

Related conditions

Clinical and Prognostic Differences among Patients with Light Chain Deposition Disease, Myeloma Cast Nephropathy and Both. Zand L et al. Leuk Lymphoma. 2015 Apr 10:1-27. [Epub ahead of print]. Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation. Afrough A et al. Biol Blood Marrow Transplant. 2015 Apr 2. pii: S1083-8791(15)00225-6.…

Emerging treatments

CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon. Laubach JP et al. Clin Cancer Res. 2015 Apr 15. pii: clincanres.3190.2015. [Epub ahead of print]. The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies. Chon HJ et al. Front Pharmacol. 2015 Mar 31;6:70. doi: 10.3389/fphar.2015.00070. eCollection 2015. Discovery of selective phosphatidylinositol 3-kinase inhibitors to treat…

Biology and genetics

APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Walker BA et al. Nat Commun. 2015 Apr 23;6:6997. doi: 10.1038/ncomms7997. Lactate, a putative survival factor for myeloma cells, is incorporated by myeloma cells through monocarboxylate transporters 1. Fujiwara S et al. Exp Hematol Oncol. 2015 Apr 21;4:12. doi: 10.1186/s40164-015-0008-z. eCollection 2015. Dutcher bodies in multiple myeloma are highly associated with translocation t(4;14) and IgA…

Supportive care

Autologous Stem-Cell Transplantation Without Hematopoietic Support for the Treatment of Hematologic Malignancies in Jehovah’s Witnesses. Ford PA et al. J Clin Oncol. 2015 Apr 13. pii: JCO.2014.57.9912. [Epub ahead of print]. Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosedmultiple myeloma patients with severe renal impairment. Zannetti BA et al. Am J Hematol. 2015 Apr 8. doi: 10.1002/ajh.24035.…

General

Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition. Stetler-Stevenson M et al. Cytometry B Clin Cytom. 2015 Apr 23. doi: 10.1002/cyto.b.21249. [Epub ahead of print]. Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma. Cejalvo MJ et al. Future Oncol. 2015 Apr 10:1-16. [Epub ahead of print]. Lenalidomide in multiple myeloma. Kim Y et al. Expert Rev Anticancer Ther. 2015 May;15(5):491-7. doi: 10.1586/14737140.2015.1033407.…

Complications of myeloma and its treatments

Thromboelastography, thrombin generation test and thrombodynamics reveal hypercoagulability in patients with multiple myeloma. Gracheva MA et al. Leuk Lymphoma. 2015 Apr 24:1-35. [Epub ahead of print]. Neurotoxicity of stem cell mobilization chemotherapy with vinorelbine in myeloma patients after bortezomib treatment. Keller S et al. Leuk Res. 2015 Mar 28. pii: S0145-2126(15)00086-7. doi: 10.1016/j.leukres.2015.03.015. [Epub ahead of print]. Subcutaneous bortezomib in multiple myeloma patients induces similar…

Current treatments

Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: Interim analysis from the prospective GMMG-MM5 trial. Merz M et al. Haematologica. 2015 Apr 3. pii: haematol.2015.124347. [Epub ahead of print]. Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT. Grövdal M et al. Bone Marrow Transplant. 2015 Apr 13.…